Screener
Collegium Pharmaceutical, Inc. COLL Belbuca — Finite-Lived Intangible Assets, Net
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Collegium Pharmaceutical, Inc. in its filing.
Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsNet.
The source filing: Collegium Pharmaceutical, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:34 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053851
| Line item | June 30, 2026 / Cost | June 30, 2026 / Accumulated Amortization | June 30, 2026 / Carrying Amount | December 31, 2025 / Cost | December 31, 2025 / Accumulated Amortization | December 31, 2025 / Carrying Amount |
|---|---|---|---|---|---|---|
| Jornay PM | $635,000 | $(152,986) | $482,014 | $635,000 | $(111,072) | $523,928 |
| Azstarys | 635,000 | (7,480) | 627,520 | — | — | — |
| Belbuca | 360,000 | (322,305) | 37,695 | 360,000 | (284,607) | 75,393 |
| Nucynta Products | 521,170 | (521,170) | — | 521,170 | (493,478) | 27,692 |
| Symproic | 70,000 | (31,145) | 38,855 | 70,000 | (27,503) | 42,497 |
| Total intangible assets | $2,221,170 | $(1,035,086) | $1,186,084 | $1,586,170 | $(916,660) | $669,510 |
Item 1. Condensed Consolidated Financial Statements (Unaudited).
FAQ
- What is Collegium Pharmaceutical, Inc.'s belbuca — finite-lived intangible assets, net?
- Collegium Pharmaceutical, Inc. (COLL) reported belbuca — finite-lived intangible assets, net of $37.7M in Q2 2026.
- How has Collegium Pharmaceutical, Inc.'s belbuca — finite-lived intangible assets, net changed year-over-year?
- Collegium Pharmaceutical, Inc.'s belbuca — finite-lived intangible assets, net decreased by 66.7% year-over-year, from $113.09M to $37.7M.
- What is the long-term trend for Collegium Pharmaceutical, Inc.'s belbuca — finite-lived intangible assets, net?
- Over 3 years (2022 to 2025), Collegium Pharmaceutical, Inc.'s belbuca — finite-lived intangible assets, net has grown at a -32.2% compound annual growth rate (CAGR), from $1.33B to $414.66M.
- What does belbuca — finite-lived intangible assets, net mean?
- The carrying value of Belbuca-related intangible assets on the balance sheet, calculated as the gross cost minus accumulated amortization and any impairment charges. It represents the remaining unamortized economic value of the product's intellectual property.
Ask your AI about Collegium Pharmaceutical, Inc.'s belbuca — finite-lived intangible assets, net.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude